Engineered bone-targeting Lycium barbarum L.-derived extracellular vesicle-like nanoparticles deliver miR167a-5p to regulate mitochondrial dynamics and metabolic reprogramming in alleviating osteoporo
3 hours ago
- #osteoporosis
- #nanomedicine
- #mitochondrial dynamics
- Engineered bone-targeting extracellular vesicle-like nanoparticles derived from Lycium barbarum L. (LB-EVLPs) deliver miR167a-5p to alleviate osteoporosis.
- The nanoparticles, functionalized with bone-targeting peptide SDSSD (BT-LB-EVLPs), target bone tissue, are internalized by bone marrow mesenchymal stem cells (BMSCs), and localize to mitochondria.
- In osteoporotic mice, BT-LB-EVLPs reduce bone loss, improve bone microstructure, enhance bone strength, and reprogram mitochondrial metabolism by boosting oxidative phosphorylation and reducing glycolysis.
- BT-LB-EVLPs attenuate oxidative stress, promote mitochondrial fusion, inhibit fission, restore mitochondrial function, and enhance osteogenic differentiation in BMSCs.
- miR167a-5p from BT-LB-EVLPs directly targets mitochondrial transporter gene SLC25A26 to regulate mitochondrial dynamics and energy metabolism, promoting osteoblastogenesis.
- Knockdown of miR167a-5p in vivo exacerbates bone loss and negates the anti-osteoporotic effects of BT-LB-EVLPs.